Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Notes Payables: 2022-2024

Historic Notes Payables for Mereo BioPharma Group (MREO) over the last 1 years, with Dec 2024 value amounting to $5.5 million.

  • Mereo BioPharma Group's Notes Payables was N/A to $5.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.5 million, marking a year-over-year change of. This contributed to the annual value of $5.5 million for FY2024, which is N/A change from last year.
  • Mereo BioPharma Group's Notes Payables amounted to $5.5 million in Q4 2024, which was down 0.29% from $5.6 million recorded in Q3 2024.
  • Mereo BioPharma Group's 5-year Notes Payables high stood at $13.3 million for Q4 2022, and its period low was $4.6 million during Q1 2024.
  • Its 2-year average for Notes Payables is $6.8 million, with a median of $5.5 million in 2024.